Literature DB >> 17093985

Lipoproteins in inflammation and sepsis. I. Basic science.

Oliver Murch1, Marika Collin, Charles J Hinds, Christoph Thiemermann.   

Abstract

BACKGROUND: High-density lipoproteins (HDL) have been shown to bind and neutralize lipopolysaccharide (LPS) and are regarded as possible therapeutic agents for sepsis and conditions associated with local or systemic inflammation. However, in recent years, a multitude of possible immunomodulatory properties other than LPS neutralization have become evident. DISCUSSION: This review highlights the advances in the understanding of how HDL is protective in both in vitro and in vivo inflammatory settings, including the ability of HDL to modulate adhesion molecule expression, upregulate endothelial nitric oxide synthase and counteract oxidative stress. Also, the active components of HDL and the recent discovery of novel lipid modulators of inflammation are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17093985     DOI: 10.1007/s00134-006-0432-y

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  75 in total

Review 1.  Year in review in intensive care medicine, 2004. III. Outcome, ICU organisation, scoring, quality of life, ethics, psychological problems and communication in the ICU, immunity and hemodynamics during sepsis, pediatric and neonatal critical care, experimental studies.

Authors:  Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker; Benoit Vallet
Journal:  Intensive Care Med       Date:  2005-02-18       Impact factor: 17.440

Review 2.  Current understanding of the metabolism and biological actions of HDL.

Authors:  Arnold von Eckardstein; Martin Hersberger; Lucia Rohrer
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2005-03       Impact factor: 4.294

3.  Comparison of the effects of aminoguanidine and N omega-nitro-L-arginine methyl ester on the multiple organ dysfunction caused by endotoxaemia in the rat.

Authors:  C C Wu; H Ruetten; C Thiemermann
Journal:  Eur J Pharmacol       Date:  1996-04-04       Impact factor: 4.432

4.  Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis.

Authors:  M Van Oosten; P C Rensen; E S Van Amersfoort; M Van Eck; A M Van Dam; J J Breve; T Vogel; A Panet; T J Van Berkel; J Kuiper
Journal:  J Biol Chem       Date:  2001-01-02       Impact factor: 5.157

5.  On the role and fate of LPS-dephosphorylating activity in the rat liver.

Authors:  Annemarie Tuin; Ali Huizinga-Van der Vlag; Anne-Miek M A van Loenen-Weemaes; Dirk K F Meijer; Klaas Poelstra
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-10-13       Impact factor: 4.052

6.  Reconstituted high density lipoprotein inhibits physiologic and tumor necrosis factor alpha responses to lipopolysaccharide in rabbits.

Authors:  J I Cué; J T DiPiro; L J Brunner; J E Doran; M E Blankenship; A R Mansberger; M L Hawkins
Journal:  Arch Surg       Date:  1994-02

7.  Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein.

Authors:  C Baumberger; R J Ulevitch; J M Dayer
Journal:  Pathobiology       Date:  1991       Impact factor: 4.342

Review 8.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

9.  Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.

Authors:  Steven Opal; Pierre-Francois Laterre; Edward Abraham; Bruno Francois; Xavier Wittebole; Stephen Lowry; Jean-Francois Dhainaut; Brian Warren; Thierry Dugernier; Angel Lopez; Miguel Sanchez; Ignace Demeyer; Luis Jauregui; Jose Angel Lorente; William McGee; Konrad Reinhart; Sascha Kljucar; Sonia Souza; John Pribble
Journal:  Crit Care Med       Date:  2004-02       Impact factor: 7.598

10.  Therapeutic effects of lysophosphatidylcholine in experimental sepsis.

Authors:  Ji-Jing Yan; Jun-Sub Jung; Jung-Eun Lee; Jongho Lee; Sung-Oh Huh; Hee-Sung Kim; Kyeong Cheon Jung; Jae-Young Cho; Ju-Suk Nam; Hong-Won Suh; Yung-Hi Kim; Dong-Keun Song
Journal:  Nat Med       Date:  2004-01-11       Impact factor: 53.440

View more
  44 in total

1.  ApoB-containing lipoproteins promote infectivity of chlamydial species in human hepatoma cell line.

Authors:  Yuriy K Bashmakov; Nailia A Zigangirova; Alexander L Gintzburg; Petr A Bortsov; Ivan M Petyaev
Journal:  World J Hepatol       Date:  2010-02-27

2.  Introduction to the lipoprotein series.

Authors:  David A Kaufman
Journal:  Intensive Care Med       Date:  2006-11-09       Impact factor: 17.440

3.  Mini-series: basic research-related reviews in intensive care medicine.

Authors:  Herwig Gerlach
Journal:  Intensive Care Med       Date:  2006-11-09       Impact factor: 17.440

4.  ICU patients: fatter is better?

Authors:  Wilfred Druml
Journal:  Intensive Care Med       Date:  2008-08-01       Impact factor: 17.440

5.  High density lipoprotein protects against polymicrobe-induced sepsis in mice.

Authors:  Ling Guo; Junting Ai; Zhong Zheng; Deborah A Howatt; Alan Daugherty; Bin Huang; Xiang-An Li
Journal:  J Biol Chem       Date:  2013-05-08       Impact factor: 5.157

Review 6.  Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response.

Authors:  Derek S Wheeler; Basilia Zingarelli; William J Wheeler; Hector R Wong
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2009-06

7.  Histone deacetylase inhibitors prevent pulmonary endothelial hyperpermeability and acute lung injury by regulating heat shock protein 90 function.

Authors:  Atul D Joshi; Nektarios Barabutis; Charalampos Birmpas; Christiana Dimitropoulou; Gagan Thangjam; Mary Cherian-Shaw; John Dennison; John D Catravas
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-23       Impact factor: 5.464

8.  Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis.

Authors:  Go Haraguchi; Hisanori Kosuge; Yasuhiro Maejima; Jun-Ichi Suzuki; Takasuke Imai; Masayuki Yoshida; Mitsuaki Isobe
Journal:  Intensive Care Med       Date:  2008-02-19       Impact factor: 17.440

9.  Death to sepsis: targeting apoptosis pathways in sepsis.

Authors:  Derek S Wheeler
Journal:  Crit Care       Date:  2009-12-07       Impact factor: 9.097

10.  Cytokines and metabolic patterns in pediatric patients with critical illness.

Authors:  George Briassoulis; Shekhar Venkataraman; Ann Thompson
Journal:  Clin Dev Immunol       Date:  2010-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.